BB265

Ulcerative colitis

Phase 1Active

Key Facts

Indication

Ulcerative colitis

Phase

Phase 1

Status

Active

Company

Australian biotech leveraging co‑cultured gut microbiome consortia to deliver regulated, scalable therapies for C. and and ulcerative colitis.

Drug	Company	Phase	Status
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active
'1805	Revolo Biotherapeutics	Phase 2 (Planned)	Active